Table 5 Prevalence of reactivity of HIV by chemiluminescence (CLIA) and nucleic acid testing (NAT).
HIV (N/%) | Total (N = 87620) | Assuit (N = 75156) | Mansoura (N = 12464) | |||
|---|---|---|---|---|---|---|
CLIA | NAT | CLIA | NAT | CLIA | NAT | |
Non-reactive | 87,598/99.97 | 87,601/99.98 | 75,140/99.98 | 75,142/98.982 | 12,458/99.95 | 12,459/99.96 |
Reactive | 22/0.03 | 19/0.02 | 16/0.02 | 14/0.018 | 6/0.05 | 5/0.04 |
HIVAg/Ab + ve NAT + ve (TP) | 19/0.02 | 14/0.018 | 5/0.04 | |||
HIVAg/Ab + ve NAT-ve (FP) | 3/0.01 | 2/0.002 | 1/0.01 | |||
HIVAg/Ab -ve NAT + ve (FN) (NAT yield) | 0/0.0 | 0/0.0 | 0/0.0 | |||
HIVAg/Ab -ve NAT-ve (TN) | 87,598/99.97 | 75,140/99.98 | 12,458/99.95 | |||
Sensitivity, Specificity, PPV, NPV and accuracy of chemiluminescence compared to gold standard test NAT (value, 95% CI) | ||||||
Sensitivity | 100.0% (81.47–100.0%) | 100.0% (76.84–100.0%) | 100.0% (47.82–100.0%) | |||
Specificity | 100.0% (99.99–100.0%) | 100.0% (99.99–100.0%) | 99.99% (99.96–100.0%) | |||
PPV | 81.82% (62.81–92.30%) | 87.50% (63.65–96.55%) | 83.33% (41.33–97.26%) | |||
NPV | 100.0% (99.9–100.0%) | 100.0% (99.9–100.0%) | 100.0% (99.97–100.0%) | |||
Accuracy | 100.00% (99.99–100.0%) | 100.00% (99.99–100.0%) | 99.99% (99.96–100.0%) | |||
Inter-rater agreement - % - Kappa coefficient value | 99.99% 0.900 (very good) | 99.99% 0.933 (very good) | 99.99% 0.909 (very good) | |||
